Barry, OppHub America Desk · · Source: prnewswire-all
ADMA Biologics Securities Fraud Lawsuit Deadline Approaches
ADMA Biologics investors with losses exceeding $100,000 between August 9, 2024, and March 25, 2026, should consider engaging legal counsel to potentially serve as lead plaintiff in a securities fraud class action lawsuit by the August 10, 2026 deadline.
Based on reporting from prnewswire-all.
Investors in ADMA Biologics (NASDAQ: ADMA) who experienced losses exceeding $100,000 between August 9, 2024, and March 25, 2026, face a critical lead plaintiff deadline of August 10, 2026. The Rosen Law Firm is leading a securities fraud class action alleging undisclosed related party transactions and channel stuffing. This matters now as affected investors must act by the August 10 deadline to potentially lead the litigation and seek compensation without upfront costs.
Market context for this story
As of: WeekendLoading quotes…
Informational only — not investment advice. Full markets →
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
$ADMA
TradingView
Live chart & market data via TradingView · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/ADMA and related $TSLA. Not investment advice.
### Money Play $ADMA+WL Biologics investors with losses exceeding $100,000 between August 9, 2024, and March 25, 2026, should consider engaging legal counsel to potentially serve as lead plaintiff in a securities fraud class action lawsuit by the August 10, 2026 deadline.
## Catalyst Analysis: Securities Fraud Allegations The Rosen Law Firm is reminding investors of $ADMA+WL Biologics, Inc. (NASDAQ: $ADMA+WL) that a securities class action lawsuit has been filed concerning alleged misrepresentations and omissions during the period of August 9, 2024, to March 25, 2026. The lawsuit claims that the company engaged in undisclosed related party transactions, utilized channel stuffing for revenue appearances, and lacked adequate internal controls. These alleged issues led to materially false and misleading statements about the company's business, operations, and prospects.
## Technical Analysis & Key Risk Watch
Key levels for $TSLA+WL (educational): R2 $322.96 · R1 $309.06 · last $308.85 · S1 $306.51 · S2 $297.38.
No specific price levels or technical indicators were provided in the verified facts for $ADMA+WL Biologics.
## Impact on $ADMA+WL Biologics Investors Investors who purchased $ADMA+WL Biologics securities within the specified Class Period and experienced losses of over $100,000 are advised that the lead plaintiff deadline is August 10, 2026. Rosen Law Firm emphasizes that participation in the class action can be pursued on a contingency fee basis, meaning no out-of-pocket fees or costs for the investors.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: August 1, 2026 at 7:06 PM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
legal risk and corporate governance
ADMA Biologics is being sued by investors who claim the company misled them about its financial health. People who lost a lot of money on this stock have until August 10, 2026, to join the legal action.
What changed
A securities fraud class action lawsuit and lead plaintiff deadline were announced for ADMA Biologics amid allegations of misleading financial practices.
Who wins / who loses
Law firms and affected plaintiffs seeking compensation benefit from organizing, while current shareholders face heightened uncertainty and potential downside risk.
Time horizon
Think in terms of the next few months.
Confidence & best fit
low confidence · Long-term investor
Low confidence → prefer ETFs and “Watch,” not rushing into one stock.
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $ADMAStay away — for now
The company is dealing with a major lawsuit, so buying the stock right now is very risky.
View $ADMA chart → · End-of-day delayed data
Second-order
- $XBIWatch — track, don’t rush
A basket of biotech stocks that lets you avoid the legal drama of one specific company.
View $XBI chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Beginners should skip options here completely because lawsuits make stock movements unpredictable.
See options-friendly brokers →Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Eligible investors with losses over $100,000 should consult legal counsel regarding lead plaintiff status.
What would break this thesis
- Dismissal of the lawsuit or a swift, favorable settlement clearing the company of wrongdoing.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from prnewswire-all.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).